Most chronic granulomatous disease patients are children 0 to 2 years old when first diagnosed, but manifestations can be delayed to the second, third or even fourth decade of life. Patients usually have short stature. Initial disease signs often involve the skin and evolve as recurrent pyodermas and abscesses of the scalp or skin folds [1] or infectious, ecxematoid or seborrheic dermatitis [2]. Other variants, described in both toddlers and newborns include pustular, papulopustular and maculopapular lesions involving the auricular, retro auricular, perioral, periorbital, perinasal, inguinal, neck, axillar or interdigital teguments. Subcutaneous abscesses rapidly develop from these lesions and have prolonged evolution.

At the time of the initial diagnosis, infection may be localized in the lungs [3], liver, spleen or bones. Pneumonia is the most frequent type of infection in these patients. Otitis, gingival abscesses, lymphadenitis or septicemia can also be initial signs of the disease. Fever is a common accompanying trait. Gastrointestinal involvement often manifests as diarrhea or intermittent bloody stools, secondary to colitis.

Associated signs include cutaneous photosensitivity, hypermelanotic macule, conjunctival secretions, as an expression of chronic blepharoconjunctivitis, serosanguineous nasal discharge, chronic suppurated paronychia and recurrent ulcerative stomatitis. The oral pain prevents alimentation and when associated with malabsorbtion leads to weight loss and failure to thrive. Hepatic and perihepatic abscesses manifest as fever and malaise. Anal region inspection sometimes highlights the presence of abscesses and fistulae [4].

Other symptoms refer to the presence of obstructive granulomas in the genito-urinary and gastrointestinal tract. Abdominal pain may be suggestive for these, but clinical diagnosis requires maintaining a high level of suspicion. Also, a brain abscess, arising from hematogenous or contiguous and spread of an infection during childhood may be suggestive for this diagnosis.

Some patients exhibit several of the symptoms discussed above by the time they present to the hospital, making clinical diagnosis much easier, while others develop signs of disease at a much slower rate. In this case, a careful history inquiry is crucial.

• Death in Childhood

  Introduction CHRONIC granulomatous disease is a heterogeneous group of uncommon inherited disorders characterized by recurrent pyogenic infections that usually begin early in life and may lead to death in childhood. 1 2 3 Two thirds of the cases involve [doi.org]

• Serosanguineous Nasal Discharge

  Associated signs include cutaneous photosensitivity, hypermelanotic macule, conjunctival secretions, as an expression of chronic blepharoconjunctivitis, serosanguineous nasal discharge, chronic suppurated paronychia and recurrent ulcerative stomatitis [symptoma.com]

• Nasal Discharge

  Associated signs include cutaneous photosensitivity, hypermelanotic macule, conjunctival secretions, as an expression of chronic blepharoconjunctivitis, serosanguineous nasal discharge, chronic suppurated paronychia and recurrent ulcerative stomatitis [symptoma.com]

• Rales

  Physical examination revealed diffuse inspiratory rales. Laboratory results showed leukocytosis. Her initial chest X-ray and CT chest showed reticular nodular interstitial lung disease pattern. [ncbi.nlm.nih.gov]

• Mild Clinical Course

  Less than 10% of patients have the X-linked variant form of CGD (X91 - ), which has a relatively mild clinical course. [emedicine.medscape.com]

  clinical course even with as little as 3% to 5% neutrophil superoxide-generating activity, serious bacterial infections or other complications typical of CGD do occur, including severe pneumonia, pulmonary fibrosis, and hepatic or perirectal abscesses [doi.org]

• High Arched Palate

  The examination showed tachypnea, crackles at the right and left base of the lung, freckles on his face, red-hair, gingivitis, a high arched palate, and retained primary dentition. Serum IgE level was markedly increased. [ncbi.nlm.nih.gov]

Laboratory studies are used in order to diagnose neutrophil dysfunction and to pinpoint the presence of infection. An usual panel must include a complete cell blood count, that will most often show peripheral leukocytosis with neutrophilia. Anemia is encountered in many cases, and the red blood cells are hypochromic and microcytic, as in most chronic inflammatory conditions. These findings are, however, nonspecific. A more eloquent test is the nitroblue tetrazolium (NBT) dye test. In vitro stimulation of the phagocytic system can be achieved by adding phorbol myristate acetate or Escherichia coli antigens in normal neutrophils, but not in diseased ones, that fail to turn oxidized nitroblue tetrazolium to formazan. This test can also be performed prenatally, but not before weeks 16 to 18 of gestation. If clinical judgment and genetic council deem appropriate, earlier diagnosis can be achieved by deoxyribonucleic acid (DNA) obtained from chorionic villi or amniotic fluid testing by polymerase chain reaction [5]. Maternal DNA contamination of the specimen can be detected by short tandem repeat analysis. However, the physician should keep in mind that obtaining the fluid or tissue specimens are invasive procedures, with unpredictable outcomes. If the nitroblue tetrazolium dye test is unavailable, the physician could order a flow cytometric reduction of dihydrorhodamine, a test that offers the same information.

As in all other diseases characterized by frequent infection, hypergammaglobulinemia can be encountered. All types of immunoglobulins can be increased, but immunoglobulin E can also be normal.

Important information for the therapeutic plan is offered by microbiological studies. Culture should be accompanied by an antibiogram to make treatment effective. Aspergillus species are frequently encountered [6], followed by Serratia, Nocardia and Burkholderia. This latter microorganism has been shown to produce more severe infections than the other two, with a resulting higher death incidence. Osteomyelitis can be caused by Staphylococcus aureus, Aspergillus nidulans or Salmonella species. Other frequently encountered catalase-positive microorganisms, such as Escherichia coli species, Klebsiella species and Listeria species. However, a trend towards an increase of age at the moment of death has been observed, due to more appropriate therapeutic plans [7].

Imaging studies offer relevant information regarding the extent of the infection. Pulmonary disease consists of lung abscesses, empyema and recurrent or persistent pneumonia. An encapsulating pneumonia is considered to be quite typical for chronic granulomatous disease, while hilar lymphadenopathy and reticulonodular lung aspects are frequently seen, as well. Computer tomography may be needed in unclear cases, as well as in patients where the suspicion of intraparenchymal abscesses are suspected.

Other useful tests, unfortunately not widely available include chemiluminescence testing, direct measurements of superoxide anion production and of oxygen consumption, polymerase chain reaction and allele-specific restriction enzyme analysis [8].

Histological analysis on skin biopsy specimens shows granulomata formation, suppurative inflammation, as well as the presence of histiocytes, neutrophils and macrophages. The periodic acid-Schiff staining reaction is positive. Necrosis areas are sometimes observed.

• Cavitary Lesion

  Lesions those are contiguous with the great vessels or the pericardium, single cavitary lesion that cause hemoptysis, lesions invading the chest wall, aspergillosis that involves the skin and the bone are the indications for surgical therapy.Chronic granulomatous [ncbi.nlm.nih.gov]

• Reticulonodular Pattern

  It may present with recurrent pneumonia, hilar lymphadenopathy, empyema, abscess, reticulonodular patterns, and granulomas due to lung involvement. In recent years, mycobacterial disease susceptibility has been reported in CGD cases. [ncbi.nlm.nih.gov]

• Nocardia Asteroides

  asteroides, Antimicrob Agents Chemother, 1988, vol. 32 (pg. 1776 - 9 ) 24 Diagnostic and therapeutic considerations in Nocardia asteroides infection, Medicine (Baltimore), 1974, vol. 53 (pg. 391 - 401 ) 25 Nocardial infections in renal transplant recipients [doi.org]

Antibiotics and prednisone represent the corner stones of medical therapy in chronic granulomatous disease [9]. Antibiotic therapy needs to be intense and prolonged and infection prophylaxis must be vigorously implemented. Broad-spectrum systemic antibiotics should be used as soon as infection is documented. In severe cases, granulocyte transfusions may be in order, especially in invasive aspergilosis cases [10].

Chronic granulomatous disease patients are immunocompromised by their disease, but also by therapy: corticosteroid administration is often required for increased periods of time and tumor necrosis factor-α (TNF-α) inhibitors, if deemed necessary for their anti-inflammatory properties, must be used with caution because of its tendency to increase the risk of potentially severe infections. Sulfasalazine and azathioprine are recommended in cases where corticoid doses need to be decreased or corticoids have caused unacceptable side effects. Hydroxychloroquine and methotrexate are used in patients suffering from lupus-like syndromes or articular inflammation. However, methotrexate treatment should be closely monitored regarding side effects, especially mucositis, that can be mistaken for manifestation of the disease itself.

After the acute infection has been eradicated, lifelong continuous prophylaxis is required and achieved by trimethoprim-sulfamethoxazole, interferon (INF)–gamma and antimycotics administration. Aspergillus species infection is usually effectively prevented by continuous itraconazole administration [11], but, if infection has already occurred, amphotericin B should be added to the therapeutic plan. Interferon-gamma subcutaneous therapy is recommended for the entire duration of the patient's life after diagnosis, due to its proven effect on monocyte and neutrophil function [12].

Hematopoietic stem cell transplantation from matched donors is another important therapeutic measure, that should be undertaken as early as possible [13]. Bone marrow transplantation is another viable option [14], but donors and recipients should be perfectly matched [15].

Surgical care in chronic granulomatous disease refers to the excision of granulomas and abscesses. Rectal abscesses can prove particularly difficult to manage, due to recurrent postoperative infection in these patients.

Gene therapy for this disease is currently undergoing clinical trials, but progress seems to already have been made by certain investigators [16].

The prognosis depends on the time clinical signs of the disease are first noted: the sooner the patient is symptomatic, the more grim the prognosis is considered to be. However, prognosis is improved by early diagnosis [17]. Life expectancy is commonly 30-40 years and death usually occurs secondary to bacterial and fungal infections [18]. Reactive oxygen intermediates are an accurate survival predictor [19]. Granulomatous complications are more frequently expected in individuals suffering from X-linked disease.

Chronic granulomatous disease is a genetic condition, with either X-linked recessive or autosomal recessive transmission. Either way, the substrate is represented by defects of one of the components of nicotinamide adenine dinucleotide phosphate oxidase, affected by regulatory-region, missense, nonsense or splice-region mutations, deletions or frame shifts [20]. Hemizygous mutations represent the vast majority. The genes that have been demonstrated to be involved are those coding the for the gp91phox, the p67phox [21], the p47phox and the p22phox components [22]. X-linked transmitted disease patients are affected by CYBB gene mutations, while autosomal recessive transmitted illness individuals suffer from NCF4, NCF1, NCF2, or CYBA genes abnormalities.

Other authors call attention to the fact that the disease may also be caused by Rac2 inhibitory mutations [23] or by bacillus Calmette-Guerin vaccination [24].

Chronic granulomatous disease is a rare pathology, affecting approximately 1 in 200,000-250,000 live births in general, with limits varying from 1 case in 1 million to 1 individual in 160.000 [25] [26]. This condition affects patients regardless of their age, but a predilection for the male sex has been observed, as in any X-linked disease [27]. Patients usually become symptomatic during the first year of life, but delayed diagnosis has also been reported [28].

The substrate of the disease consists in the inability of the phagocytes to destroy the microorganisms. Their microbe ingestion ability, however, remains unaffected [29]. The dysfunction of the nicotinamide adenine dinucleotide phosphate (NADPH) oxidase enzyme complex makes patients prone to develop catalase-positive organisms infections. Microorganisms that are resistant to nonoxidative killing are another source of morbidity and mortality.

Two mechanisms of microorganism survival inside the phagocyte have been postulated. One refers to a direct role of reactive oxygen species, while the other discusses their implication in proteolytic enzymes release form the phagocyte granules [30]. Both mechanisms may be implicated in disease pathophysiology. Phagocytes that have ingested microorganisms but are unable to destroy them organize into granulomata, located in the skin, gastrointestinal tract, lungs, bones, liver or lymph nodes.

As in most genetic diseases, primary prevention is only applicable to the potential offspring of the patients, by means of genetic counseling. Secondary prophylaxis is achieved by early diagnosis and treatment of infections and offering advice on infection avoidance.

Chronic granulomatous disease is an infrequent pathology affecting males more frequently than females, defined by phagocytic dysfunction as a result of X-linked or autosomal recessive mutation of either one of the five domains of the nicotinamide adenine dinucleotide phosphate oxidase. The genetic abnormality causes the inability to generate superoxide, a vital component of phagocytic mediated immunity. Symptoms are initially more or less severe [31], but the propensity for severe infection persists throughout the entire lifetime. Early diagnosis and aggressive treatment are crucial for patient survival and wellbeing. Therapeutic measures consist of aggressive bacterial and fungal treatment followed by continuous, life-long prophylaxis trimethoprim-sulfamethoxazole, itraconazol and interferon (INF)–gamma administration. Gene therapy is an option in certain cases, whereas others benefit from allogeneic hematopoietic stem cell transplantation or bone marrow transplantation.

Chronic granulomatous disease is a rare genetic condition affecting white blood cells, that are responsible for the immunity. Genetic diseases are present at birth, therefore symptoms usually arise during the childhood, even the first year of life, despite the fact that the child appears healthy at birth. An immune system deficiency implies the fact that the body is vulnerable to infection that would not represent a problem for otherwise healthy individuals. For chronic granulomatous disease patients, even initially minor infections can become lethal in time. Milder forms, that go unrecognized during the teenage period or even adulthood are also possible.

Medical tests patients are subjected to aim to diagnose and locate the infection and its etiological agent and to establish the type of dysfunction of the immune system (since this condition is characterized by the fact that antibody production, for instance, remains normal). Once the genetic substrate has been identified, the only curative treatment remains gene therapy, but good results have been achieved with allogeneic hematopoietic stem cell transplantation and bone marrow transplantation. However, before that, the patient will most likely require prolonged and repeated hospitalization periods that make bacterial and fungal infection treatment possible. Their prevention partially lies in the hands of the patient, who is strongly advised to pay special attention to skin hygiene, an important entry point for dangerous microbes.

1. Carnide EG, Jacob CA, Castro AM, Pastorino AC. Clinical and laboratory aspects of chronic granulomatous disease in description of eighteen patients. Pediatr Allergy Immunol. 2005 Feb. 16(1):5-9.
2. Chowdhury MM, Anstey A, Matthews CN. The dermatosis of chronic granulomatous disease. Clin Exp Dermatol. 2000 May. 25(3):190-4.
3. Sarwar G, de Malmanche T, Rassam L, Grainge C, Williams A, Arnold D. Chronic granulomatous disease presenting as refractory pneumonia in late adulthood. Respirol Case Rep. 2015. 3(2):54-6.
4. Marciano BE, Rosenzweig SD, Kleiner DE, et al. Gastrointestinal involvement in chronic granulomatous disease. Pediatrics. 2004 Aug. 114(2):462-8.
5. De Boer M, Singh V, Dekker J, Di Rocco M, Goldblatt D, Roos D. Prenatal diagnosis in two families with autosomal, p47-phox-deficient chronic granulomatous disease due to a novel point mutation in NCF1. Prenat Diagn. 2002;22:235–240.
6. Beaute J, Obenga G, Le Mignot L, et al. Epidemiology and outcome of invasive fungal diseases in patients with chronic granulomatous disease: a multicenter study in France. Pediatr Infect Dis J 2011; 30:57–62.
7. van den Berg JM, van Koppen E, Ahlin A, et al. Chronic granulomatous disease: the European experience. PLoS One 2009; 4:e5234.
8. Agudelo-Florez P, Lopez JA, Redher J, et al. The use of reverse transcription-PCR for the diagnosis of X-linked chronic granulomatous disease. Braz J Med Biol Res. 2004 May. 37(5):625-34.
9. Yamazaki-Nakashimada MA, Stiehm ER, Pietropaolo-Cienfuegos D, Hernandez-Bautista V, Espinosa-Rosales F. Corticosteroid therapy for refractory infections in chronic granulomatous disease: case reports and review of the literature. Ann Allergy Asthma Immunol. 2006 Aug. 97(2):257-61.
10. Wang J, Mayer L, Cunningham-Rundles C. Use of GM-CSF in the treatment of colitis associated with chronic granulomatous disease. J Allergy Clin Immunol. 2005 May. 115(5):1092-4.
11. Gallin JI, Alling DW, Malech HL, et al. Itraconazole to prevent fungal infections in chronic granulomatous disease. N Engl J Med. 2003 Jun 12. 348(24):2416-22.
12. Marciano BE, Wesley R, De Carlo ES, et al. Long-term interferon-gamma therapy for patients with chronic granulomatous disease. Clin Infect Dis. 2004 Sep 1. 39(5):692-9.
13. Martinez CA, Shah S, Shearer WT, et al. Excellent survival after sibling or unrelated donor stem cell transplantation for chronic granulomatous disease. J Allergy Clin Immunol. 2012 Jan. 129(1):176-83.
14. Åhlin A, Fugeläng J, de Boer M, Ringden O, Fasth A, Winiarski J. Chronic granulomatous disease – haematopoietic stem cell transplantation versus conventional treatment. Acta Paediatr. 2013;102:1087–1094.
15. Seger RA, Gungor T, Belohradsky BH, et al. Treatment of chronic granulomatous disease with myeloablative conditioning and an unmodified hemopoietic allograft: a survey of the European experience, 1985-2000. Blood. 2002 Dec 15. 100(13):4344-50.
16. Ott MG, Schmidt M, Schwarzwälder K, et al. Correction of X-linked chronic granulomatous disease by gene therapy, augmented by insertional activation of MDS1-EVI1, PRDM16 or SETBP1. Nat Med. 2006;12:401–409
17. Agarwal S. Chronic Granulomatous Disease. J Clin Diagn Res. 2015. 9(5):1-2.
18. Marciano BE, Spalding C, Fitzgerald A, et al. Common severe infections in chronic granulomatous disease. Clin Infect Dis. 2015. 60(8):1176-83.
19. Kuhns DB, Alvord WG, Heller T, et al. Residual NADPH oxidase and survival in chronic granulomatous disease. N Engl J Med. 2010 Dec 30. 363(27):2600-10.
20. Jurkowska M, Bernatowska E, Bal J. Genetic and biochemical background of chronic granulomatous disease. Arch Immunol Ther Exp (Warsz). 2004 Mar-Apr. 52(2):113-20.
21. Noack D, Rae J, Cross AR, et al. Autosomal recessive chronic granulomatous disease caused by defects in NCF-1, the gene encoding the phagocyte p47-phox: mutations not arising in the NCF-1 pseudogenes. Blood. 2001 Jan 1. 97(1):305-11.
22. Rae J, Noack D, Heyworth PG, Ellis BA, Curnutte JT, Cross AR. Molecular analysis of 9 new families with chronic granulomatous disease caused by mutations in CYBA, the gene encoding p22(phox). Blood. 2000 Aug 1. 96(3):1106-12.
23. Segal BH, Leto TL, Gallin JI, Malech HL, Holland SM. Genetic, biochemical, and clinical features of chronic granulomatous disease. Medicine (Baltimore). May 2000. 79(3):170-200.
24. Vieira AP, Vasconcelos J, Fernandes JC, et al. Lymphadenopathy after BCG vaccination in a child with chronic granulomatous disease. Pediatr Dermatol. 2004 Nov-Dec;21(6):646-51.
25. Ahlin A, De Boer M, Roos D, et al. Prevalence, genetics and clinical presentation of chronic granulomatous disease in Sweden. Acta Paediatr. 1995 Dec. 84(12):1386-94.
26. Oh HB, Park JS, Lee W, Yoo SJ, Yang JH, Oh SY. Molecular analysis of X-linked chronic granulomatous disease in five unrelated Korean patients. J Korean Med Sci. 2004 Apr. 19(2):218-22.
27. Roos D, de Boer M. Molecular diagnosis of chronic granulomatous disease. Clin Exp Immunol. 2014. 175(2):139-49.
28. Fijolek J, Wiatr E, Gawryluk D, Bestry I, Bernatowska E, Jablonski W. Chronic granulomatous disease recognised in 42-years-old patient. Pneumonol Alergol Pol. 2008. 76(1):58-65.
29. Segal BH, Romani L, Puccetti P. Chronic granulomatous disease. Cell Mol Life Sci. 2009 Feb. 66(4):553-8.
30. Reeves EP, Lu H, Jacobs HL, et al. Killing activity of neutrophils is mediated through activation of proteases by K+ flux. Nature. 2002;416:291–297.
31. Roos D, de Boer M. Molecular diagnosis of chronic granulomatous disease. Clin Exp Immunol. 2014. 175(2):139-49.